ArticleGut and liver2026
Metabolic Dysfunction-Associated Steatotic Liver Disease and Vascular Complications: Associations with Serum Testosterone Levels in a Korean Multicenter Male Cohort.
Article in Gut and liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06843421 (Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry: A Retrospective Multicenter Cross-Sectional Study (K-MASLD Registry)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: We investigated the associations of testosterone levels with metabolic dysfunction-associated steatotic liver disease (MASLD) and vascular complications in a large Korean male cohort. Despite the high global prevalence of MASLD and significant morbidity from cardiovascular disease, the interplay among testosterone levels, MASLD, and vascular outcomes remains unclear, particularly in Asian populations. Methods: This cross-sectional study analyzed 1,167 men from the Korean Health Screening-Based MASLD Registry. MASLD was defined as imaging-confirmed steatosis with metabolic dysfunction. Log2-transformed testosterone levels were analyzed using logistic regression adjusted for metabolic risk factors to evaluate associations with MASLD, advanced fibrosis (Fibrosis-4 index [FIB-4] ≥1.3), carotid plaques, and cerebrovascular accidents (CVAs). Results: Among the 1,167 men (mean age 57.0 years), 730 (62.6%) had MASLD. These patients had lower testosterone levels than non-MASLD men did (223.5 ng/dL vs 347.5 ng/dL; p<0.001) and showed adverse metabolic features. Higher testosterone levels were independently associated with reduced risk of MASLD (odds ratio [OR], 0.89; 95% confidence interval [CI], 0.85 to 0.94; p<0.001). Among the MASLD patients, higher testosterone levels were linked to a significantly lower prevalence of carotid plaques (OR, 0.77; 95% CI, 0.73 to 0.81) and CVAs (OR, 0.75; 95% CI, 0.67 to 0.82). The associations remained robust across sensitivity analyses with adjustments for obesity, diabetes, and dyslipidemia. No significant association was observed with advanced fibrosis (FIB-4 ≥1.3). Conclusions: Low testosterone levels are independently associated with MASLD and its vascular complications but not with advanced fibrosis. Serum testosterone levels may serve as a practical biomarker for metabolic and vascular risk stratification in MASLD patients, warranting validation in prospective and interventional studies. (ClinicalTrials.gov identifier NCT06843421).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.